| 2026-03-16 |
股东大会：
将于2026-04-13召开股东大会
会议内容 ▼▲
- 1.The election of seven nominees to our board of directors;
2.The ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;
3.The approval, on a non-binding advisory basis, of the compensation of our named executive officers;
4.The adoption and approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued shares of common stock at a ratio within the range of not less than 1-for-30 and not more than 1-for-50, with the exact ratio within such range and the implementation and timing of such reverse stock split to be determined at the sole discretion of our board of directors without further approval or authorization of our stockholders;
5.The transaction of any other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2026-03-16 |
详情>>
股本变动：
变动后总股本9766.08万股
|
| 2026-03-16 |
详情>>
业绩披露：
2025年年报每股收益-0.28美元,归母净利润-2660.2万美元,同比去年增长34.60%
|
| 2025-12-30 |
详情>>
内部人交易：
Sarraf Pasha共交易5笔
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.31美元,归母净利润-2818.6万美元,同比去年增长9.60%
|
| 2025-08-12 |
详情>>
业绩披露：
2025年中报每股收益-0.24美元,归母净利润-2073.9万美元,同比去年增长7.90%
|
| 2025-05-12 |
详情>>
业绩披露：
2025年一季报每股收益-0.17美元,归母净利润-1225.7万美元,同比去年增长0.73%
|
| 2025-04-25 |
股东大会：
将于2025-06-04召开股东大会
会议内容 ▼▲
- 1.To adopt and approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our capital stock from 210,000,000 to 310,000,000 and increase the number of authorized shares of our common stock from 200,000,000 to 300,000,000;
2.The election of six nominees to the Board of Directors;
3.The ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
4.The approval, on a non-binding advisory basis, of the compensation of our named executive officers;
5.The approval of the Cue Biopharma, Inc. 2025 Stock Incentive Plan;
6.The transaction of any other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-0.72美元,归母净利润-4067.4万美元,同比去年增长19.83%
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.62美元,归母净利润-3117.8万美元,同比去年增长16.41%
|
| 2024-09-10 |
股东大会：
将于2024-10-08召开股东大会
会议内容 ▼▲
- 1.To adopt and approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our capital stock from 110,000,000 to 210,000,000 and increase the number of authorized shares of our common stock from 100,000,000 to 200,000,000;
2.To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation of proxies in the event that there are insufficient votes for the adoption and approval of Proposal 1.
|
| 2024-08-14 |
详情>>
业绩披露：
2024年中报每股收益-0.45美元,归母净利润-2251.8万美元,同比去年增长14.36%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.25美元,归母净利润-1234.7万美元,同比去年增长5.81%
|
| 2024-04-26 |
股东大会：
将于2024-06-05召开股东大会
会议内容 ▼▲
- 1.The election of six nominees to the Board of Directors;
2.The ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.The approval, on a non-binding advisory basis, of the compensation of our named executive officers;
4.The transaction of any other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-03-28 |
详情>>
业绩披露：
2023年年报每股收益-1.11美元,归母净利润-5073.3万美元,同比去年增长4.30%
|
| 2023-11-03 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.82美元,归母净利润-3729.9万美元,同比去年增长2.91%
|
| 2023-04-28 |
股东大会：
将于2023-06-07召开股东大会
会议内容 ▼▲
- 1.The election of seven nominees to the Board of Directors;
2.The ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.The approval, on a non-binding advisory basis, of the compensation of our named executive officers;
4.The recommendation, on a non-binding advisory basis, of the frequency of future advisory votes on the compensation of our named executive officers;
5.The transaction of any other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2022-04-29 |
股东大会：
将于2022-06-09召开股东大会
会议内容 ▼▲
- 1.The election of seven nominees to the Board of Directors;
2.The ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.The transaction of any other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-26 |
股东大会：
将于2021-06-09召开股东大会
会议内容 ▼▲
- 1.The election of seven nominees to the Board of Directors;
2.The ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2020-05-29 |
股东大会：
将于2020-07-09召开股东大会
会议内容 ▼▲
- 1.To elect the seven nominees to the Board of Directors nominated by the Board of Directors.
2.To approve an amendment to our Certificate of Incorporation increasing the number of authorized shares of common stock from 50,000,000 shares to 100,000,000 shares.
3.To ratify the appointment of RSM US LLP as our independent registered public accounting firm for 2020.
4.To transact such other business as may properly come before the annual meeting and any adjournments or postponements thereof.
|
| 2019-06-18 |
股东大会：
将于2019-08-06召开股东大会
会议内容 ▼▲
- 1.To elect the nine nominees to the Board of Directors nominated by the Board of Directors.
2.To ratify the appointment of RSM US LLP as our independent registered public accounting firm for 2019.
3.To approve an amendment to our Certificate of Incorporation to establish a classified Board of Directors initially consisting of nine members to be divided into three classes.
4.To approve Amendment No. 1 to the Cue Biopharma, Inc. 2016 Omnibus Incentive Plan, which increases the number of shares that may be issued pursuant to incentive stock options thereunder.
5.To transact such other business as may properly come before the annual meeting and any adjournments or postponements thereof.
|
| 2018-04-30 |
股东大会：
将于2018-06-12召开股东大会
会议内容 ▼▲
- 1.To elect the seven nominees to the Board of Directors nominated by the Board of Directors.
2.To ratify the appointment of Gumbiner Savett Inc. as our independent registered public accounting firm for 2018.
3.To transact such other business as may properly come before the annual meeting and any adjournments or postponements thereof.
|